Efficacy of two-time prophylactic intravenous administration of tazobactam/piperacillin for transrectal ultrasound-guided needle biopsy of the prostate.

Prevalence of fluoroquinolone (FQ)-resistant Escherichia coli has been recently increasing worldwide. We analyzed the incidence and characteristics of acute bacterial prostatitis after transrectal ultrasound-guided needle prostate biopsy (TRUSP-Bx) with prophylactic tazobactam/piperacillin (TAZ/PIPC) treatment as an alternative regimen.

A total of 391 patients who underwent TRUSP-Bx were included in the study. All patients received intravenous TAZ/PIPC (4. 5 g) 30 minutes before and 6 hours after TRUSP-Bx.

Acute bacterial prostatitis developed in six patients (1. 5%); the frequency of its occurrence was significantly higher in patients in whom rectal disinfection was not performed (P < 0. 05). These six patients developed clinical symptoms of acute bacterial prostatitis a median of 24 hours after the biopsy. Escherichia coli was isolated in urine or blood bacterial cultures in four cases, and Klebsiella pneumoniae in two cases. All of the isolated organisms showed excellent sensitivity to TAZ/PIPC.

The incidence rate of acute prostatitis with prophylactic TAZ/PIPC was consistent with those reported previously with FQ-based regimens, despite the favorable sensitivity of isolated organisms. Two-time regimen of TAZ/PIPC may not always prevent the post-TRUSP-Bx infection, possibly due to the pharmacokinetic characteristics of TAZ/PIPC. However, if each case was considered individually to select the best setting and frequency of dosage of TAZ/PIPC, this can be an optimal prophylaxis in the era of widespread FQ-resistant microorganisms.

Prostate international. 2015 Jul 17 [Epub]

Hiroaki Iwamoto, Kazuyoshi Shigehara, Tohru Miyagi, Takao Nakashima, Masayoshi Shimamura, Mikio Namiki

Department of Urology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan ; Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan. , Department of Urology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan. , Department of Urology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan. , Department of Urology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan. , Department of Urology, Nomi City Hospital, Nomi, Japan. , Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe